Role of CA125 in Predicting Ovarian Cancer Survival - a Review of the Epidemiological Literature

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2009 Oct 13

PMID 19818123

Citations 75

Authors

Digant Gupta

Christopher G Lis

Affiliations

Soon will be listed here.

Abstract

CA125 is the gold standard tumor marker in ovarian cancer. Serum level of CA125 is used to monitor response to chemotherapy, relapse, and disease progression in ovarian cancer patients. Thus, it is reasonable to investigate whether CA125 may have utility as a prognostic indicator as well in ovarian cancer. A large number of epidemiological studies have been carried out to this effect. This review summarizes all available epidemiological literature on the association between CA125 levels and survival in ovarian cancer. To place these studies in context, we provide some background information on CA125 and its role in ovarian cancer.

Citing Articles

TiC/FeO - based surface plasmon resonance imaging biosensor for efficient separation and sensitive detection of CA125 in serum.

Zou Z, Chen Y, Sun R, Shi B, Jiang L, Huang F Mikrochim Acta. 2025; 192(3):168.

PMID: 39960621 DOI: 10.1007/s00604-024-06906-z.

Extracellular Vesicles, Circadian Rhythms, and Cancer: A Comprehensive Review with Emphasis on Hepatocellular Carcinoma.

Fekry B, Ugartemendia L, Esnaola N, Goetzl L Cancers (Basel). 2024; 16(14).

PMID: 39061191 PMC: 11274441. DOI: 10.3390/cancers16142552.

Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer.

Englisz A, Smycz-Kubanska M, Mielczarek-Palacz A Diagnostics (Basel). 2024; 14(9).

PMID: 38732363 PMC: 11083226. DOI: 10.3390/diagnostics14090949.

Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer.

Kallio H, Savolainen K, Virtanen T, Ryyppo L, Selin H, Martikainen P Life Sci Alliance. 2024; 7(6).

PMID: 38580393 PMC: 10997860. DOI: 10.26508/lsa.202402658.

An exploration of the effect of Chinese herbal compound on the occurrence and development of large intestine cancer and intestinal flora.

Liu P, Ying J, Guo X, Tang X, Zou W, Wang T Heliyon. 2024; 10(1):e23533.

PMID: 38173486 PMC: 10761579. DOI: 10.1016/j.heliyon.2023.e23533.

References

Makar A, Kristensen G, Kaern J, Bormer O, Abeler V, Trope C . Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol. 1992; 79(6):1002-10. View

Hunter V, Daly L, Helms M, Soper J, Berchuck A, Clarke-Pearson D . The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol. 1990; 163(4 Pt 1):1164-7. DOI: 10.1016/0002-9378(90)90680-6. View

Rustin G, Nelstrop A, Tuxen M, Lambert H . Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996; 7(4):361-4. DOI: 10.1093/oxfordjournals.annonc.a010602. View

Eisenkop S, Spirtos N, Friedman R, Lin W, Pisani A, Perticucci S . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003; 90(2):390-6. DOI: 10.1016/s0090-8258(03)00278-6. View

Juretzka M, Barakat R, Chi D, Iasonos A, Dupont J, Abu-Rustum N . CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol. 2006; 104(1):176-80. DOI: 10.1016/j.ygyno.2006.07.027. View

Colakovic S, Lukic V, Mitrovic L, Jelic S, Susnjar S, Marinkovic J . Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers. 2000; 15(2):147-52. DOI: 10.1177/172460080001500204. View

Munstedt K, Krisch M, Sachsse S, Vahrson H . Serum CA 125 levels and survival in advanced ovarian cancer. Arch Gynecol Obstet. 1997; 259(3):117-23. DOI: 10.1007/BF02505319. View

Davidson N, Khanna S, Kirwan P, Bircumshaw D . Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. Clin Oncol (R Coll Radiol). 1991; 3(1):32-6. DOI: 10.1016/s0936-6555(05)81038-6. View

Hoskins P, Eisenhauer E, Vergote I, Fisher B, Grimshaw R, Oza A . Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol. 2000; 18(24):4038-44. DOI: 10.1200/JCO.2000.18.24.4038. View

10.

Tuxen M, Soletormos G, Dombernowsky P . Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer. 2001; 84(10):1301-7. PMC: 2363637. DOI: 10.1054/bjoc.2001.1787. View

11.

Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T . Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol. 1995; 58(1):42-7. DOI: 10.1006/gyno.1995.1181. View

12.

Gadducci A, Cosio S, Fanucchi A, Negri S, Cristofani R, Genazzani A . The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol. 2004; 93(1):131-6. DOI: 10.1016/j.ygyno.2003.12.043. View

13.

Skates S, Menon U, MacDonald N, Rosenthal A, Oram D, Knapp R . Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol. 2003; 21(10 Suppl):206s-210s. DOI: 10.1200/JCO.2003.02.955. View

14.

Geisler J, Miller G, Lee T, Harwood R, Wiemann M, Geisler H . Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. J Reprod Med. 1996; 41(3):140-2. View

15.

Rustin G, Marples M, Nelstrop A, Mahmoudi M, Meyer T . Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001; 19(20):4054-7. DOI: 10.1200/JCO.2001.19.20.4054. View

16.

Markman M . Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin North Am. 2003; 17(4):957-68, viii. DOI: 10.1016/s0889-8588(03)00058-3. View

17.

Crawford S, Peace J . Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?. Ann Oncol. 2004; 16(1):47-50. DOI: 10.1093/annonc/mdi012. View

18.

Rapkiewicz A, Espina V, Petricoin 3rd E, Liotta L . Biomarkers of ovarian tumours. Eur J Cancer. 2004; 40(17):2604-12. DOI: 10.1016/j.ejca.2004.05.021. View

19.

Bast Jr R, Feeney M, Lazarus H, Nadler L, Colvin R, Knapp R . Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981; 68(5):1331-7. PMC: 370929. DOI: 10.1172/jci110380. View

20.

van der Burg M, Lammes F, van Putten W, Stoter G . Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol. 1988; 30(3):307-12. DOI: 10.1016/0090-8258(88)90244-2. View